СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПАТОГЕНЕЗЕ И КЛАССИФИКАЦИИ РОЗАЦЕА

DOI: https://doi.org/10.29296/25877305-2019-03-03
Скачать статью в PDF
Номер журнала: 
3
Год издания: 
2019

Е. Снарская, доктор медицинских наук, профессор, Т. Русина Первый МГМУ им. И.М. Сеченова (Сеченовский Университет) E-mail: rusina@cidk.ru

Представлен обзор литературы по вариантам патогенеза розацеа. Рассматриваются эпидемиология и распространенность этой патологии в популяции, классификация, указаны факторы, провоцирующие заболевание, а также связи розацеа с генетическими факторами, действием микроорганизмов, нарушением функции пищеварительного тракта, патологией эндокринной и нервной систем, изменением иммунного статуса.
Ключевые слова: 
дерматология
розацеа
патогенез
классификация
обзор
Для цитирования
Снарская Е., Русина Т. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПАТОГЕНЕЗЕ И КЛАССИФИКАЦИИ РОЗАЦЕА . Врач, 2019; (3): 17-21 https://doi.org/10.29296/25877305-2019-03-03

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Бутов Ю.С., Скрипкин О.К., Иванов О.Л. Дерматовенерология / М.: ГЭОТАР-Медиа, 2013. [Butov Yu.S., Skripkin O.K., Ivanov O.L. Dermatovenerologiya / M.: GEOTAR-Media, 2013 (in Russ.)].
  2. Катханова О.А., Катханов А.М., Стенин А.В. Комплексная терапия акнеформных дерматозов // Эксперим. и клин. дерматокосметол. – 2014; 2: 12–8 [Katkhanova O.A., Katkhanov A.M., Stenin A.V. Combination therapy for acneiform dermatoses // Eksperimental’naya i klinicheskaya dermatokosmetologiya. – 2014; 2: 12–8 (in Russ.)].
  3. Олисова О.Ю., Кочергин Н.Г., Смирнова Е.А. Инновации в наружной терапии розацеа // Российский журнал кожных и венерических болезней. – 2017; 20 (5): 270–4 [Olisova O.Yu., Kochergin N.G., Smirnova E.A. Innovations to topical therapy of rosacea // Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. – 2017; 20 (5): 270–4 (in Russ.)].
  4. Потекаев Н.Н., Демидова Л.М., Шугинина Е.А. Микротоковая терапия: перспективы применения в косметологии; роль микротоков в лечении розацеа // Вестник эстетической медицины. – 2010; 9 (3): 6–12 [Potekayev N.N., Demidova L.M., Shugunina E.A. Microcurrent therapy: application perspective in cosmetology; microcurrents’ role in healing patients with rosacea // Vestnik esteticheskoy meditsiny. – 2010; 9 (3): 6–12 (in Russ.)] .
  5. Свирщевская Е.В., Матушевская Е.В., Матушевская Ю.И. Актуальные вопросы патогенеаза и терапии розацеа // Клиническая дерматология и венерология. – 2017; 4: 4–12 [Svirshchevskaya E.V., Matushevskaya E.V., Matushevskaya Yu.I. Modern questions in rosacea pathogenesis and therapy // Klinicheskaya dermatologiya i venerologiya. – 2017; 4: 4–12 (in Russ.)] DOI: 10.17116/klinderma20171644-13.
  6. Abram K., Silm H., Maaroos H. et al. Risk factors associated with rosacea // J. Eur. Acad. Dermatol. Venereol. – 2010; 24: 565–71.
  7. Abram. K., Silm H., Oona M. Prevalence of rosacea in an Estonian working population using a standard classification // Acta Derm. Venereol. – 2010; 90: 269–73.
  8. Ansel J., Armstrong C., Song I. et al Interactions of the skin and nervous system // J. Investig. Dermatol. Symp. Proc. – 1997; 2: 23–6.
  9. Bhatia N., Del Rosso J. Optimal management of papulopustular rosacea: rationale for combination therapy // J. Drugs Dermatol. – 2012; 11 (7): 838–44.
  10. Chang A., Raber I., Xu J. et al. Assessment of the genetic basis of rosacea by genome-wide association study // J. Invest. Dermatol. – 2015; 135: 1548–55.
  11. Chen Y., Moore C., Zhang J. et al. TRPV4 moves toward center-fold in rosacea pathogenesis // J. Invest. Dermatol. – 2017; 137: 801–4.
  12. Crawford G., Pelle M., James W. Rosacea: I. Etiology, pathogenesis, and subtype classification // J Am. Acad. Dermatol. – 2004; 51: 327–41.
  13. Del Rosso J. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema // J. Clin. Aesthet. Dermatol. – 2012; 5: 16–25.
  14. Dirschka T., Tronnier H., Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis // Br. J. Dermatol. – 2004; 150: 1136–41.
  15. Duman N., Ersoy Evans S., Atakan N. Rosacea and cardiovascular risk factors: a case control study // J. Eur. Acad. Dermatol. Venereol. – 2014; 28: 1165–9.
  16. Egeberg A., Hansen P., Gislason G. et al. Patients with rosacea have increased risk of depression and anxiety disorders: A danish nationwide cohort study // Dermatology. – 2016; 232: 208–13.
  17. Ekiz O., Balta I., Sen B.B. et al. Vitamin D status in patients with rosacea // Cutan Ocul. Toxicol. – 2014; 33 (1): 60–2.
  18. Gerber P., Buhren B., Steinhoff M. et al. Rosacea: The cytokine and chemokine network // J. Investig. Dermatol. Symp. Proc. – 2011; 15: 40–7.
  19. Gravina A., Federico A., Ruocco E. et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea // United Eur. Gastroenterol. J. – 2015; 3: 17–24.
  20. Guzman-Sanchez D., Ishiuji Y., Patel T. et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea // J. Am. Acad. Dermatol. – 2007; 57: 800–5.
  21. Halder R., Brooks H., Callender V. Acne in ethnic skin // Dermatol. Clin. – 2003; 21 (4): 609–15.
  22. Helfrich Y., Maier L., Cui Y. et al. Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging // JAMA Dermatol. – 2015; 151: 825–36.
  23. Herr H., You C. Relationship between Helicobacter pylori and rosacea: It may be a myth // J. Korean Med. Sci. – 2000; 15: 551–4.
  24. Del Rosso J. Розацеа кожи: патогенез, клинические проявления, современные рекомендации по тактике ведения пациентов // Вестн. дерматол. и венерол. – 201; 2: 21–31 [Del Rosso J. Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management // Vestnik dermatologii i venerologii. – 2016; 2: 21–31 (In Russ.)]. https://doi.org/10.25208/0042-4609-2016-0-2-21-31.
  25. Kyriakis K., Palamaras I., Terzoudi S. et al. Epidemiologic aspects of rosacea // J. Am. Acad. Dermatol. – 2005; 53: 918–9.
  26. Li S., Cho E., Drucker A. et al. Alcohol Intake and Risk of Rosacea in US Women // J. Am. Acad. Dermatol. – 2017; 76: 1061–7.
  27. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host response // Nature. – 2006; 442: 39–44.
  28. Motley R., Barton S., Marks R. The signifi cance of telangiectasia in rosacea. In: Acne and Related Disorders: An International Symposium/ Wales: Martin Dunitz: Cardiff, 1989; p. 339–44.
  29. Muto Y., Wang Z., Vanderberghe M. et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea // J. Invest. Dermatol. – 2014; 134: 2728–36.
  30. Peters E. Stressed skin? – A molecular psychosomatic update on stress-causes and effects in dermatologic diseases // J. Dtsch. Dermatol. Ges. – 2016; 14: 233–52.
  31. Rainer B., Fischer A., Luz Felipe da Silva D. et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study // J. Am. Acad. Dermatol. – 2015; 73: 604–8.
  32. Ramelet A. Rosacea: a reaction pattern associated with ocular lesions and migraine? // Arch. Dermatol. – 1994; 130: 1448.
  33. Ramtin Kassir, Aparanjita Kolluru, Martin Kassir. Intense pulsed light for the treatment of Rosacea and Telangiectasias //J. Cosmetic Laser Ther. – 2006; 13 (5): 216–22.
  34. Rice W., Weiss S. Regulation of proteolysis at the neutrophilsubstrate interface by secretory leukoprotease inhibitor // Science. – 1990; 249: 178–81.
  35. Rios-Yuil J., Mercadillo-Perez P. Evaluation of Demodex folliculorum as a Risk Factor for the Diagnosis of Rosacea In Skin Biopsies. Mexico’s General Hospital (1975–2010) // Indian J. Dermatol. – 2013; 58: 157.
  36. Salzer S., Kresse S., Hirai Y. et al. Cathelicidin peptide LL-37 increases UVBtriggered inflammasome activation: possible implications for rosacea // J. Dermatol. Sci. – 2014; 76: 173–9.
  37. Schwab V., Sulk M., Seeliger S. et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea // J. Investig. Dermatol. Symp. Proc. – 2011; 15: 53–62.
  38. Steinhoff M., Schauber J., Leyden J. New insights into rosacea pathophysiology: a review of recent findings // J. Am. Acad. Dermatol. – 2013; 69: 15–26.
  39. Sulk M., Seeliger S., Aubert J. et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea // J. Invest. Dermatol. – 2012; 132: 1253–62.
  40. Two A., Wu W., Gallo R. et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors // J. Am. Acad. Dermatol. – 2015; 72: 749–58; quiz 59–60.
  41. Vieira A., Mannis M. Ocular rosacea: Common and commonly missed // J. Am. Acad. Dermatol. – 2013; 69: 36–41.
  42. Wang T., Nestel F., Bourdeau V. et al. Cutting edge: 1,25-dihydroxy vitamin D3 is a direct inducer of antimicrobial peptide gene expression // J. Immunol. – 2004; 73 (5): 2909–12.
  43. West J., Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease // Lancet. – 1992; 340: 762–7.
  44. Wilkin J., Dahl M., Detmar M. et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea // J. Am. Acad. Dermatol. – 2002; 46: 584–7.
  45. Wilkin J. Oral thermal-induced flushing in erythematotelangiectatic rosacea // J. Inves.t Derm. – 1981; 76: 15–8.
  46. Wollina U. Recent advances in the understanding and management of rosacea // F1000Prime Rep. – 2014; 6: 50.
  47. Yamasaki K., Gallo R. The molecular pathology of rosacea // J. Dermatol. Sci. – 2009; 55: 77–81.
  48. Melnik B. Rosacea: The blessing of the celts – an approach to pathogenesis through translational research // Acta Derm. Venereol. – 2016; 96 (2): 147–56.